Cross Species Genetics Transhumanism
Thank You Chris HohnFrom:Pale BlueViews:0 0ratingsTime:14:59More inEducation

Here is the original post:
Cross Species Genetics

Recommendation and review posted by Bethany Smith

Flip Out Vol 2 - Full Album (320kbps)
2002 - Flip Out Vol 2 - Mixed By Oforia (VA) Tracklist: 1. BLT - Genetics 2. GMS - Black Hole 3. Joti Sidhu - Downpusher 4. Kamasutrance vs Groove-A-Tech - Life Force 5. Electric Universe - Embrace It 6. Lemurians - Identification 7. Psydrop - Radical Command 8. Space Buddha - I Think Therefore I AmFrom:PsychedelicPowerViews:0 0ratingsTime:51:47More inMusic

See the rest here:
Flip Out Vol 2 - Full Album (320kbps) - Video

Recommendation and review posted by Bethany Smith

Colic Baby Relief | Remedies for Colic in newborns | Treatment for Colicky Babies
A colic baby is a newborn that suffers from an attack of crying from what appears to be intestinal pain. It is a fairly common condition and affects roughly 20% of babies. All infants cry when they are hungry, tired, hot or cold, or because of a dirty diaper. It is the only way for them to communicate their needs to us. Unfortunately, colicky babies also cry sometimes even after being cleaned, fed and warm cozy. Your may have a colic baby if he or she appears to be healthy but still suffers from frequent inconsolable crying. If this is the case, you need to seek relief for your loved one. Roughly 20% of newborns are colic babies. Most experts believe that it is not the result of genetics, pregnancy or childbirth issues. Some of the possible causes of a colicky baby are overstimulated senses, Infant acid reflux, immature digestive system (having difficulties digesting certain foods), food allergies/sensitivity and maternal smoking. This ailment is episodic. It can be irritated by improper diaper changing techniques, overfeeding and emotional stress. Doing research is always great but it is important that you consult a doctor to seek treatment if you suspect colic in a newborn. For more information, please visit: en.wikipedia.org Consoling and relieving a colic baby is difficult but there are remedies you can use to help. Here are a few treatments that may provide relief (but always talk to a pediatrician first). 1. Watch what you eat 2. Switch formulas 3. Consider ...From:ServiceFox1Views:0 0ratingsTime:03:41More inFilm Animation

More here:
Colic Baby Relief | Remedies for Colic in newborns | Treatment for Colicky Babies - Video

Recommendation and review posted by Bethany Smith

Value of plant genetics to the community
GUEST: Peter Davies - Plant Physiologist and US Department of State Science FellowFrom:ANCalertsViews:8 0ratingsTime:09:57More inNews Politics

Read more:
Value of plant genetics to the community - Video

Recommendation and review posted by Bethany Smith

Virtual Girl Girls Dancing Virtual Girls in Your Desktop
Virtual Girl Girls! virtualgirlgirls.com Axelle Parker Golden Eyes Origins: Antibes / France - Age: 19 Height: 5.51 - Weight: 110 - Vital Statistics: 35/24/35 Her unusual appearance is the result of interesting genetics. Axelle tells us that she is part Eskimo and part French. Not many women can say that, but if you look at the results, you #39;ll be wishing a lot more Frenchmen would start mixing with Eskimo women because the beauty that results from that genetic coupling is definitely something to smile about! Categories: Bikini, High Heels, Trimmed, Blonde, European Facebook! http://www.facebook.com Twitter! http://www.twitter.comFrom:alanscraigViews:0 0ratingsTime:01:58More inEntertainment

Read more:
Virtual Girl Girls Dancing Virtual Girls in Your Desktop - Video

Recommendation and review posted by Bethany Smith

Earnings momentum for Myriad Genetics (MYGN) has been on the rise ever since this molecular diagnostic company released strong fiscal first-quarter results earlier this month that included an upbeat guidance. Shares of this Zacks #1 Rank (Strong Buy) have also advanced and reached a 52-week high of $30.48 on November 14. With a robust portfolio, a strong earnings surprise history, increased guidance and a year-to-date return of 45.7%, Myriad Genetics offers an attractive investment opportunity. Excellent Quarter On November 5, Myriad Genetics reported fiscal first-quarter earnings per share of 36 cents, beating the Zacks Consensus Estimate by 12.5% and the year-ago earnings by 24%. The company has now delivered positive earnings surprises for 7 straight quarters with an average beat of 9.1%. Revenues increased 21% year over year to $133.4 million, beating the Zacks Consensus Estimate of $130.0 million. Myriad's two businesses - Molecular diagnostic testing and Companion diagnostic services - recorded revenues of $127.3 million (up 22% year over year) and $6.2 million (down 4.6%), respectively. The company's flagship product, Bracanalysis (representing 78.7% of total revenues during the quarter), has been growing robustly over the past few quarters on the back of increasing penetration in both the Oncology and Women's Health markets. In the last reported quarter, this product recorded a 17% jump in revenues to $105 million. In addition, revenues derived from Colaris and Colaris AP, which assess a patient's risk of developing hereditary colorectal and uterine cancers, increased 26% to $12.1 million. Moreover, the company is enjoying a strong and diversified pipeline across six major medical specialties. In the last earnings call, Myriad's announcement of its expected launch of molecular diagnostic test Melapath in 2013 has acted as another impetus in driving the share price higher. Melapath is expected to play a ground-breaking role in determining whether a skin biopsy is malignant or benign. The company is confident about the potential of Melapath, which has achieved 95% accuracy in predicting which suspicious skin lesions are malignant and has an anticipated market opportunity of $400 million a year in the US. Furthermore, the company has progressed in receiving reimbursements for the BART (Brac Analysis Large Rearrangement Technology) test. The Noridian Administrative Services announced that Medicare would reimburse the test for patients with a personal history of breast or ovarian cancer from October 1, 2012 onwards. Myriad has already started receiving huge number of testing requests. Upbeat Guidance Myriad Genetics raised its outlook for fiscal 2013. The company now expects revenues between $570 million and $585 million (previous guidance was $550-$565 million), reflecting growth of 15-18%. The raised guidance is primarily based on an improved outlook for the Molecular Diagnostics segment, which is expected to gross $545 million to $557 million in the fiscal year. The guidance for the Companion diagnostic remained unchanged at $25 million to $28 million. Earnings per share for the fiscal year is likely to be in a range of $1.50 to $1.55, up from the previous range of $1.44-$1.48. Rising Earnings Estimates Over the past 30 days, the Zacks Consensus Estimate for 2012 has gained 5.4% to $1.55 per share, thanks to upward revisions from all 13 estimates. This represents year-over-year growth of about 18.9%. Meanwhile, the Zacks Consensus Estimate for 2013 is up 4.7% to $1.77 on positive revisions from 12 of 13 estimates. This indicates growth of about 14.7% year over year. Chart Reflects Strength Myriad's price performance has been reasonably strong with the chart showing an upward trend. Following the release of its first quarter results, the stock showed a steep uptrend and is currently trading above both its 50- and 200-day averages. A series of earnings beats, rising estimates and upbeat growth prospects make Myriad worth considering as a momentum stock. Headquartered in Salt Lake City, Utah, Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. So far, Myriad has launched nine commercial molecular diagnostic products, including five predictive medicine (designed to assess an individual's risk for developing a disease later in life), three personalized medicine (identification of a patient's probability of responding to drug therapy) and one prognostic medicine (assess a patient's risk of disease progression and recurrence) product. Myriad has a market capitalization of $2.45 billion. Want More of Our Best Recommendations? Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential. Learn More>>

Read more from the original source:
Myriad Genetics - Momentum

Recommendation and review posted by Bethany Smith

Earnings momentum for Myriad Genetics (MYGN) has been on the rise ever since this molecular diagnostic company released strong fiscal first-quarter results earlier this month that included an upbeat guidance. Shares of this Zacks #1 Rank (Strong Buy) have also advanced and reached a 52-week high of $30.48 on November 14. With a robust portfolio, a strong earnings surprise history, increased guidance and a year-to-date return of 45.7%, Myriad Genetics offers an attractive investment opportunity.

Excellent Quarter

On November 5, Myriad Genetics reported fiscal first-quarter earnings per share of 36 cents, beating the Zacks Consensus Estimate by 12.5% and the year-ago earnings by 24%. The company has now delivered positive earnings surprises for 7 straight quarters with an average beat of 9.1%.

Revenues increased 21% year over year to $133.4 million, beating the Zacks Consensus Estimate of $130.0 million. Myriad's two businesses - Molecular diagnostic testing and Companion diagnostic services - recorded revenues of $127.3 million (up 22% year over year) and $6.2 million (down 4.6%), respectively.

The company's flagship product, Bracanalysis (representing 78.7% of total revenues during the quarter), has been growing robustly over the past few quarters on the back of increasing penetration in both the Oncology and Women's Health markets. In the last reported quarter, this product recorded a 17% jump in revenues to $105 million. In addition, revenues derived from Colaris and Colaris AP, which assess a patient's risk of developing hereditary colorectal and uterine cancers, increased 26% to $12.1 million.

Moreover, the company is enjoying a strong and diversified pipeline across six major medical specialties. In the last earnings call, Myriad's announcement of its expected launch of molecular diagnostic test Melapath in 2013 has acted as another impetus in driving the share price higher. Melapath is expected to play a ground-breaking role in determining whether a skin biopsy is malignant or benign. The company is confident about the potential of Melapath, which has achieved 95% accuracy in predicting which suspicious skin lesions are malignant and has an anticipated market opportunity of $400 million a year in the US.

Furthermore, the company has progressed in receiving reimbursements for the BART (Brac Analysis Large Rearrangement Technology) test. The Noridian Administrative Services announced that Medicare would reimburse the test for patients with a personal history of breast or ovarian cancer from October 1, 2012 onwards. Myriad has already started receiving huge number of testing requests.

Upbeat Guidance

Myriad Genetics raised its outlook for fiscal 2013. The company now expects revenues between $570 million and $585 million (previous guidance was $550-$565 million), reflecting growth of 15-18%. The raised guidance is primarily based on an improved outlook for the Molecular Diagnostics segment, which is expected to gross $545 million to $557 million in the fiscal year. The guidance for the Companion diagnostic remained unchanged at $25 million to $28 million. Earnings per share for the fiscal year is likely to be in a range of $1.50 to $1.55, up from the previous range of $1.44-$1.48.

Rising Earnings Estimates

Read more:
Myriad Genetics (MYGN): Zacks Rank Buy

Recommendation and review posted by Bethany Smith

SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics, Inc. (Pink Sheets:VRAL) today announced it will change its name to VG Life Sciences, Inc. and implement a 1-for-600 reverse split of its common stock. The name change and the reverse stock split are expected to be become effective on or about November 26, 2012, pending review and acceptance by FINRA. Both the name change and the reverse stock split were approved by a majority of the Companys shareholders after recommendation by the Board of Directors of the Company. This corporate action and name change followed an earlier increase to authorized common stock of the Company in October 2012 and changes to the terms of the Companys Series A Preferred Shares in August 2012.

The Board of Directors took these actions for several important reasons, said Haig Keledjian, Viral Genetics CEO. The primary reason is the strength of our science and our intellectual property portfolio. We have worked long and hard to build our IP and to begin moving some of the molecules and compounds from our basic science and discovery efforts into clinical trials at prestigious medical institutions. In order to accelerate our movement down this path we are revamping our corporate structure into a more credible format. This new capital structure gives us more credibility with potential business partners, institutional funding sources, and the new executive talent that we are seeking to hire as we move from a basic research-oriented company and develop our capabilities as an operating drug development business.

The name change reinforces our evolution from a purely R&D focus, continued Mr. Keledjian. VG Life Sciences, Inc. more accurately depicts our intellectual property and the business focus which is broader than pharmaceuticals and now reaches into biofuels, agricultural technology and other high-growth industries.

As a significant shareholder of the Company and someone who has devoted more than 15 years of my life to its success, my intention going forward is to build value on this newly established base, concluded Mr. Keledjian.

Interim Increase to Authorized Common Share Capital

In October 2012, the Board recommended and a majority of shareholders approved an increase to the authorized common stock of the Company, increasing the authorized common stock from 1,500,000,000 common shares to 3,000,000,000 common shares. At the time of the increase, there were approximately 1,500,000,000 common shares issued and outstanding with additional share issuance obligations due. The Board believed an increase to authorized common shares was required in order to meet these interim obligations during the FINRA review period for the reverse stock split. Without this increase, the Company would have defaulted in meeting those obligations.

Debt Settlements and Payments

In connection with the increase to authorized common stock of the Company, the Company recently settled portions of certain outstanding debts.

On September 14, 2012, the Company agreed to amend the terms of certain outstanding convertible debentures and unsecured advances (the 2012 Debentures) totaling $848,500, representing cash advanced to the Company by an arms-length private investor over the past 18 months. The 2012 Debentures originally allowed the conversion of outstanding principal into shares of common stock at the investors option at varying prices but generally at $0.0025. Because of the decrease in the Companys common stock price and the pending maturity of several of the 2012 Debentures, the investor was unlikely to exchange their debt for common shares, and would likely demand repayment in cash. The Company was not in a position to repay this debt in cash. The Company and the investor agreed to amend the 2012 Debentures, such that the 2012 Debentures will be settled and paid through the issuance of a total of approximately 920 million shares of common stock issuable over the next 12 months, upon the maturity of each portion of the debt, without any further consent required by the investor. The effective conversion price of the issuances is a weighted average price of $0.00092. Under the terms of the underlying 2012 Debentures, the investor may not engage in any conversions of debt to shares including under the amended terms if upon receipt of such shares they would beneficially own an aggregate number of shares greater than 9.99% of the total issued and outstanding common shares of the Company. To date, the Company has paid a total of $55,000 of the amended 2012 Debentures through the issuance of a total of approximately 222 million shares of common stock, leaving $793,500 due and payable through the issuance of an additional approximately 698 million shares of common stock over the next year.

Read more:
Viral Genetics Announces Details of Corporate Restructuring, Including Name Change, Reverse Stock Split and Increase ...

Recommendation and review posted by Bethany Smith

CGD Society - Gene Therapy film - Prof. Adrian Thrasher
In this film, Prof. Adrain Thrasher of the UCL Institute of Child Health, England, talks about the progress that has been made with gene therapy over recent years. He explains that while gene therapy is not currently a long-term alternative to bone marrow transplantation for patients with CGD, it is an option for those who are seriously ill.From:CGDSocietyViews:1 0ratingsTime:04:47More inNonprofits Activism

Read this article:
CGD Society - Gene Therapy film - Prof. Adrian Thrasher - Video

Recommendation and review posted by Bethany Smith

GENETICS 3: GENE THERAPY
GENE THERAPYFrom:drjahn41Views:0 0ratingsTime:01:00More inScience Technology

Originally posted here:
GENETICS 3: GENE THERAPY - Video

Recommendation and review posted by Bethany Smith

Dr. Tsilfidis on XIAP Gene Therapy
XIAP gene therapy is unique madi-in-Canada therapy for retinal disease. Developed by Dr. Catherine Tsilfidis and her colleagues at the University of Ottawa and the Ottawa Hospital Research Institute, the treatment aims to slow cell death in the retina and preserve vision. Promising findings show that the therapy can potentially halt cell death in many conditions including retinitis pigmentosa and retinal detachment, preventing further vision loss. Learn more about XIAP Gene Therapy in this short video interview with Dr. Tsilfidis (1:30 minutes). Footage provided by: Accessible Media Inc. (www.ami.ca)From:FFBCanadaViews:1 0ratingsTime:01:31More inEducation

Read more:
Dr. Tsilfidis on XIAP Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Favorable patent decision involves rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease

Atlanta, Georgia (PRWEB) November 20, 2012

In the companys news yesterday,

Cardium Therapeutics announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease. Cardiums Generx gene therapy candidate, which employs these key methods, is currently in late-stage clinical studies.

Cardiums patent portfolio now includes allowed and issued patents covering its gene therapy approach both in Europe and in the United States, with competing patent applications licensed and pursued by Boston Scientific having been successfully overcome in both Europe and the U.S.

The competing patent applications licensed by Boston Scientific Corporation had been the subject of opposition proceedings in Europe and interference proceedings in the United States, both of which were ultimately resolved in Cardiums favor. After further examining Cardiums case, the European Patent Office approved Cardiums patent application for grant in Europe. Three corresponding U.S. Patents that had been challenged by Boston Scientific Corporation have been affirmed in the favor of Cardium.

Cardium has additional patents and patent applications involving its methods of cardiovascular gene therapy in the U.S., Europe, Russia, and in other parts of the world, and the company recently filed new patent applications involving certain improved techniques for the treatment of heart disease that are currently the subject of a Phase 3 registration trial based in Moscow, which is designed to generate additional safety and effectiveness data for the Russian Federation and other jurisdictions. Generx (alferminogene tadenovec) is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents. Its safety and effectiveness have been the subject of clinical studies involving more than 650 patients in the U.S., Europe, and elsewhere. Generx has been assigned the trade name Cardionovo for planned commercialization in the Russian Federation. Cardium believes that its Generx clinical database represents the largest and most complete gene therapy dossier and is directed to a major medical indication that is a leading cause of death throughout the developed world.

The resolution of these important reviews of our gene therapy patents, and the consistent decisions in our favor including rulings by the U.S. courts of appeal, underscore the value of our patent portfolio, which we believe reflects a breakthrough approach to the treatment of coronary heart disease, stated Dr. Tyler M. Dylan-Hyde, Chief Business Officer and General Counsel of Cardium Therapeutics.

Recently-published findings demonstrate that Cardiums innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after one-time intracoronary administration of adenovector in mammalian hearts. Two consecutive but brief periods of coronary artery occlusion combined with co-administration of nitroglycerin increased both adenovector presence (measured by PCR) and transgene expression (assessed by luciferase activity) by over two orders of magnitude (>100 fold) in the heart, as compared to prior intracoronary artery delivery methods.

The research results published in Human Gene Therapy Methods extend those findings and demonstrate that Cardiums new technique for adenovector gene delivery in the heart can be used to dramatically boost adenovector delivery. By enhancing uptake even in patients with less severe forms of disease and ischemia, it would be expected to reduce response variability and allow for the potential treatment of patients with a broader range of associated coronary artery disease. The new treatment protocols for Cardiums recently-initiated ASPIRE clinical study have been developed to use this improved knowledge about induced transient ischemia techniques to enhance the non-surgical, catheter-based delivery of Generx to the heart.

View post:
MissionIR News - Cardium Therapeutics Wins IP Protection for Cardiovascular Gene Therapy

Recommendation and review posted by Bethany Smith

cord blood registry | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com These diseases include blood related, genetic and neurotic disorders. ""Banking the umbilical cord blood when your baby is born is a relatively new idea, the first operation using it to help cure a child with Leukemia was only done a little over 10 years ago. After processing of cells, comes the next procedure of cord blood preservation. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. A man can change his god-gifted features wishfully with the help of science. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. With people not fully understanding how important stem cells could be for us, everybody agrees that more research need to be done in order to help understand all that. If there is any complication during delivery, the entire idea is abandoned. It is always wise to preserve this waste blood of the baby which is otherwise thrown away. You are injecting the patient with those same cells that created him!This can be done with the bone marrow transplants tooYes, stem cells are found in bone marrows too. It is a simple and ...From:luisantafeViews:0 0ratingsTime:01:31More inScience Technology

Read the original:
cord blood registry | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Recommendation and review posted by simmons

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.

The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."

Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks

Read this article:
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy

Recommendation and review posted by simmons

NeoStem, Inc. (NYSE:NBS ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)", grant number 2R44DE022493-02A1, from the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). This peer reviewed grant is to support a Phase 2 investigation and first approved NIH clinical study of VSELsTM in humans. The study will be headed by Denis O. Rodgerson, Ph.D., Director of Grants and Academic Liaison for NeoStem, in collaboration with co-investigators Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment for this study is expected to begin in 2013.

This award will fund the evaluation of VSELTM stem cells as a potential treatment for periodontitis. The product candidate, an autologous therapy derived from a patient's own stem cells, is to be developed for use in the regeneration of bone tissue damaged by this disease. The award includes $706,682 for the first year and $515,172 for the second year of the project, and will cover the cost of the Investigational New Drug (IND) submission to the FDA for the product candidate.

Dr. Denis O. Rodgerson, Director of Grants and Academic Liaison for NeoStem, said, "We are pleased and honored that NIH has agreed to support further studies on bone regeneration by using VSELTM stem cells. This is an extension of our successful NIH funded collaboration with Dr. Taichman showing the production of human bone from human VSELsTM in a mouse model."

Periodontal disease is prevalent in the U.S. and affects up to 90% of the world population. The most severe cases of periodontal disease affect between 5% and 15% of the U.S. population, or between 15 and 47 million Americans. The incidence of periodontal disease is estimated to be between 1 and 3 million Americans annually, and growing at a 7% rate each year. Studies have shown that periodontal inflammation could have a role in the initiation or progression of coronary heart disease and stroke. Market research experts have estimated that severe periodontal disease represents a market between $1.25 and $1.5 billion annually.

Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership, Department of Periodontics & Oral Medicine, University of Michigan stated, "I am thrilled for the possibilities that this award opens. The chance to continue to partner with NeoStem to further develop regenerative therapies is significant. The validation that this award brings and the opportunity to establish a proof of concept, which may impact human health, is truly rewarding." Dr. Laurie McCauley, The William K. and Mary Anne Najjar Professor, Division of Periodontics Department of Periodontics and Oral Medicine, University of Michigan added, "This novel cell based therapeutic approach looks to validate scientifically sound pre-clinical studies and provide a vital translation to improved human patient care."

NeoStem has a worldwide exclusive license to VSEL technology which uses very small embryonic-like stem cells, a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. NeoStem has shown that very small embryonic-like stem cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what it believes to be an important population of stem cells that may have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative biological effects associated with embryonic stem cells.

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are very excited about this important step of funding for what will be the first human clinical study for our VSELTM technology. Not only will this study expand our knowledge of how autologous cell therapy can treat periodontitis and other bone defects, but it represents a milestone for NeoStem as we move our development of VSELTM technology beyond animal models and into the clinic, paving the way for other potential VSELTM trials."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

Read this article:
NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans

Recommendation and review posted by simmons

Therafit Gym Multiple Sclerosis Jody MS (stem cell trial).wmv
PLEASE SEND THE LETTER BELOW TO YOUR US SENATORS! We are writing to encourage the FDA and the Center for Biologics Evaluation and Research (CBER) to approve a clinical trial of mesenchymal stem cell derived neural progenitors (MSC-NPs) in the treatment of Secondary Progressive Multiple Sclerosis (SPMS). The initial 20 person trial will be conducted at the Multiple Sclerosis Research Center of New York (MSRCNY) under the direction of Dr. Saud Sadiq, neurologist and director of the MSRCNY. Dr. Sadiq was previously the head of Neurology at St. Luke #39;s Roosevelt Hospital in New York City (NYC). In 2006, he started this research center in NYC working only on MS. In November 2011, the MSRCNY received approval from the Institutional Review Board (IRB) of the International Cellular Medicine Society (ICMS) to conduct this trial for patients with SPMS, the first of its kind ever done in the US. This trial is very specialized as it uses a patient #39;s own adult stem cells that are removed from the patient #39;s breast bone marrow, grown, isolated and injected into the spinal fluid (intrathecal) where the disease attacks the myelin. The trial will last for 3 years with stem cell treatments every 3 months for the first year and potentially more, depending on the many evaluations to determine physical and mental progress. MSRCNY requested approval in the past and is currently seeking approval for this trial AGAIN!! We are at a breakthrough point in the treatment of patients with SPMS. These ...From:therafitgymViews:11 0ratingsTime:08:46More inNonprofits Activism

Read more:
Therafit Gym Multiple Sclerosis Jody MS (stem cell trial).wmv - Video

Recommendation and review posted by simmons

SC12 Attendees Say Keep Producing Tools to Further Research (Tim Carroll)
@SC12 Dell #39;s Tim Carroll: 125 customer meetings and thousands of people through the booth say: keep producing tools to help the world #39;s research, whether it #39;s small genomics clusters for personalized medicine or the #7 system in the world. http://www.tacc.utexas.edu http://www.dellhpcsolutions.com httpFrom:Janet BartlesonViews:1 0ratingsTime:00:58More inScience Technology

See more here:
SC12 Attendees Say Keep Producing Tools to Further Research (Tim Carroll) - Video

Recommendation and review posted by sam

stem cell | Pros And Cons Of Cord Blood Storage Or Cord Blood Banking
http://www.cordbloodrecommendation.com After the therapy has done, the patient is then infused using cord blood through a Hickman catheter. Cord blood collection, whether pre or post delivery, entails no pains and risk for both mother and child. 2. There are many diseases that can be treated with stem cells, so if your child ever needs stem cells later in his/her life, you will not have to look for a new donor. Placental and cord blood banking may become even more valuable in the future with exciting research under way to find new medical uses in areas such as: diabetes, heart disease, liver disease, muscular dystrophy, Alzheimer #39;s disease, Parkinson #39;s disease, stroke, and even spinal cord injury. However, in the event that you actually need the cord blood, I am sure there is no price too high for a parent to be willing to pay. In a second time, advances in knowledge of the different types of stem cells and their function will undoubtedly allow soon, the development of new therapies with the ability to repair the dermis of irradiated people and those with big burns. 4) Company Stability Since a baby #39;s stem cells may be stored for a lifetime, it is important to know that the company chosen is stable. Stem cell cord blood has higher probability of becoming the perfect match for family members and relatives and has no risk of rejection by the recipient #39;s body. Yet, with more people considering cord blood banking, whether privately or publicly, it is likely that more miracles can ...From:myc0kyViews:0 0ratingsTime:01:31More inScience Technology

Follow this link:
stem cell | Pros And Cons Of Cord Blood Storage Or Cord Blood Banking - Video

Recommendation and review posted by sam

Bert Burns Speaks as Summa Rehab Hospital
When Bert Burns suffered a life-changing injury in his 20s after being thrown from his car during an accident, no one would have blamed him if he decided life as he knew it was over. Facing his future as a quadriplegic, he could have easily viewed the outcome as the end rather than a beginning. Instead, Bert discovered his spinal cord injury to be a blessing in disguise, allowing him to realize dreams that he never would have had before being injured. Today he speaks across the nation, working to help others reclaim their life.From:Summa RehabViews:3 0ratingsTime:10:22More inSports

Read more:
Bert Burns Speaks as Summa Rehab Hospital - Video

Recommendation and review posted by sam

How to Perform a Transfer (T1 SCI)
How to properly initiate a wheelchair to bed transfer for a thoracic level 1 spinal cord injury.From:abeveridge89Views:3 0ratingsTime:01:09More inEducation

Here is the original post:
How to Perform a Transfer (T1 SCI) - Video

Recommendation and review posted by sam

Vanessa Laura Marano : A Night By The Ocean Gala with Meaghan Martin
Vanessa and Laura Marano hit the carpet at the Life Rolls On Foundation #39;s 2012 Night by the Ocean Gala held at the Ritz-Carlton Hotel in Los Angeles on Saturday night (November 10). Joined by good friend Meaghan Martin, the young actresses came out to support the foundation which has raised more than one million dollars to support quality of life programs for young people affected by spinal cord injury. "Oh, and I literally had the best time ever at #LifeRollsOn #NightByTheOcean last night! Everyone there is amazing including @katieleclerc :D" Laura tweeted afterwards. Read more: http://www.justjaredjr.comFrom:MrDisneyKingTVViews:0 0ratingsTime:00:21More inEntertainment

Go here to read the rest:
Vanessa

Recommendation and review posted by sam

SWORTEC MotionMaker trade;
"While there #39;s life, there #39;s hope" - Marcus Tullius Cicero Neurological patients with movement disorders caused by spinal cord injury, traumatic brain injury, stroke, multiple sclerosis or other neurological diseases, such as cerebral palsy can profit from our patented treatment with MotionMaker trade; and CLEMS trade; electro stimulation. SWORTEC has developed a novel interactive training device and system working closely with leading research institutes and clinics. The new medical technology combines two types of therapy: Functional Electrical Stimulation (FES), enhanced by the central control unit Patient-tailored movement program, that can significantly improve voluntary muscle control in the lower limbs. The development of voluntary muscle control is a vital part of the rehabilitation process, and essential if the patient is to gain maximum benefit from any walk re-education training and activity. Our MotionMaker trade; system is successfully applied at several renowned clinics and research institutes in Switzerland: the SUVA-Care Rehabilitation centre (CRR) in Sion, Swiss Paraplegics Centre (SPC) in Notwill, and the medico-educational centre La Castalie in Monthey. http://www.swortec.chFrom:Samy EisensteinViews:1 0ratingsTime:00:57More inScience Technology

Read this article:
SWORTEC ® MotionMaker™ - Video

Recommendation and review posted by sam

My name is Seth and this is my continuing story part 3
This is part 3 in my ongoing video diary entries describing life with a Spinal Cord injury. These entries are meant to motivate and inspire those who think their current situation is beyond hope and life would be extremely difficult or impossible to live. It is also informative for those who might need information related to a spinal cord injury but do not know where to look.From:havnfun370Views:0 0ratingsTime:08:55More inPeople Blogs

Link:
My name is Seth and this is my continuing story part 3 - Video

Recommendation and review posted by sam

Wise Young, MD, PhD at the 2012 Spinal Cord Workshop
Wise Young, MD, PhD Founding Director, WM Keck Center for Collaborative Neuroscience Professor, Department of Cell Biology and Neuroscience Richard H. Shindell Chair in Neuroscience Rutgers, The State University of New Jersey Talk title: Umbilical cord blood and lithium treatment of chronic spinal cord injuryFrom:bedfordstemcellViews:0 0ratingsTime:54:07More inScience Technology

Excerpt from:
Wise Young, MD, PhD at the 2012 Spinal Cord Workshop - Video

Recommendation and review posted by sam

Ed Wirth, MD, PhD at the 2012 Spinal Cord Workshop
Ed Wirth, MD, PhD Spinal Cord Injury Clinical Scientist Talk title: Cell-Based Therapies for SCI: Lessons Learned in Planning and Conducting Two Phase 1 Safety Trials Over the Past 18 YearsFrom:bedfordstemcellViews:1 1ratingsTime:50:36More inScience Technology

Originally posted here:
Ed Wirth, MD, PhD at the 2012 Spinal Cord Workshop - Video

Recommendation and review posted by sam